Gliora (nanoolaparib/nanotemozolomide) / Nanoform - LARVOL DELTA

A new kernel, a nanoformulated combination of olaparib (Lynparza originally developed by AstraZeneca Plc) and temozolomide (Temodar originally developed by Merck & Company Inc.), as a locally-administered, long-acting, thermo-responsive hydrogel, for the treatment of high-grade glioma, announced in partnership with Revio Therapeutics (Nanoform Press Release) - "Under the agreement, development costs and all licensing and commercial revenues will be shared equally between the partners, with Nanoform receiving an additional €1.5 million in accelerated revenue-share payments....Prototype development and testing is at an advanced stage, and the program is expected to be in the clinic by H2 2026. Subject to successful co-development and commercialization, GLIORA could be commercially available by 2029-30."

Launch • Licensing / partnership • Glioma